Primary cutaneous plasmacytoma

Int J Hematol. 2017 May;105(5):545-546. doi: 10.1007/s12185-017-2203-7. Epub 2017 Feb 28.

Authors

Mitsuhiro Matsuda¹, Sanae Sueda², Takahide Taniguchi²

Affiliations

¹ Department of Hematology, PL General Hospital, 2204 Shindo, Tondabayashi, Osaka, 584-8585, Japan. matsuda@plhospital.or.jp.
² Department of Hematology, PL General Hospital, 2204 Shindo, Tondabayashi, Osaka, 584-8585, Japan.

PMID: 28247190
DOI: 10.1007/s12185-017-2203-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antigens, CD / metabolism
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Bortezomib / administration & dosage
Cell Transformation, Neoplastic / pathology
Cyclophosphamide / administration & dosage
Dexamethasone / administration & dosage
Female
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Gene Rearrangement
Humans
Immunoglobulin Heavy Chains / genetics
Immunoglobulin M / metabolism
Middle Aged
Multiple Myeloma / diagnosis*
Multiple Myeloma / drug therapy
Multiple Myeloma / genetics
Multiple Myeloma / pathology*
Plasma Cells / metabolism
Plasma Cells / pathology
Positron-Emission Tomography*
Proto-Oncogene Proteins c-bcl-6 / genetics
Radiopharmaceuticals
Skin Neoplasms / diagnosis*
Skin Neoplasms / drug therapy
Skin Neoplasms / genetics
Skin Neoplasms / pathology*
Treatment Outcome

Substances

Antigens, CD
BCL6 protein, human
Biomarkers, Tumor
Fluorine Radioisotopes
Immunoglobulin Heavy Chains
Immunoglobulin M
Proto-Oncogene Proteins c-bcl-6
Radiopharmaceuticals
Fluorodeoxyglucose F18
Bortezomib
Dexamethasone
Cyclophosphamide